|Previous Section||Index||Home Page|
Mr. Clegg: To ask the Secretary of State for Health what date has been set for the commencement of the planned public consultation regarding the possible inclusion of graphic or pictorial warnings on cigarette packets as permitted by EU Directive 2001/37/EC. 
Caroline Flint: 5,000 individuals were reported to the national drug treatment monitoring system (NDTMS) in 200405 in community-based treatment, specialist prescribing, general practitioner prescribing, structured day programmes, structured counselling, other structured treatment, with the main problem drug of crack cocaine.
Ms Rosie Winterton: As of April 2006, primary care trusts (PCTs) will be responsible for commissioning primary care dentistry. It will therefore be up to individual PCTs to decide what the most appropriate services are, based on the needs of their local populations.
Julia Goldsworthy: To ask the Secretary of State for Health pursuant to the Written Ministerial Statement of 9 November 2005, Official Report, columns 1718WS, on national health service dentistry, how many of the 1,400 new dentists will be placed in (a) the general dental service, (b) salaried primary care dental services and (c) the hospital dental service. 
Ms Rosie Winterton: A precise breakdown of the information requested is not available. However, the vast majority of the 1,459 whole-time equivalent dentists are working in general dental services or personal dental services with a small number working in the salaried primary care dental services. None of the 1,459 dentists are working in the hospital dental service.
Mr. Randall: To ask the Secretary of State for Health what the average cost was of a national health service dental check-up in (a) England, (b) London and (c) Uxbridge constituency in each of the last 10 years for which figures are available. 
Mr. Randall: To ask the Secretary of State for Health what percentage of the population was registered with an NHS dentist in (a) England, (b) London, (c) the London borough of Hillingdon and (d) Uxbridge constituency in each of the last 10 years for which figures are available. 
Ms Rosie Winterton: The information available is shown in the tables. Information on people registered with a national health service dentist in the Uxbridge constituency is not provided as population data are not available at this level.
|London borough of Hillingdon|
Ms Rosie Winterton: The number of national health service dentists and number of patients registered in Welwyn Hatfield Primary Care Trust as at 30 September in each year specified, are provided in the table.
Mr. Lansley: To ask the Secretary of State for Health what the functions of her Department's performance support team; how many staff it has; and what the differences are between the roles of the performance support team and the turnaround teams she announced in her statement of 1 December 2005, Official Report, column 37WS, on NHS Finance. 
Mr. Byrne: The performance support team is a national health service team which works with a small number of hospital trusts which need additional support in meeting the clinical and .managerial requirements of the NHS Plan. It has 23 employees.
Turnaround teams will comprise of experts with a mix of commercial and NHS turnaround skills. The first stage of their work was a baseline assessment with those organisations with the largest financial challenges. The first phase assessed 62 organisations and the second 35. Following the initial assessments, they will agree a tailored package of turnaround support with the organisations facing the largest risks and with their strategic health authority. This will help them to achieve financial balance and provide services more efficiently.
Mr. Blizzard: To ask the Secretary of State for Health what the annual level of prescribing of (a) carmustie implants and (b) temozolomide outside the context of clinical trials was in the last three years for which figures are available, broken down by (i) strategic health authority and (ii) primary care trust. 
The estimated cost of temozolomide and carmustine dispensed in hospitals and in the community (primary care) in England over the last three financial years is shown in the table.
8 Feb 2006 : Column 1309W
|Dispensed in hospitals||2,758.9||3,126.9||4,336.9|
|Dispensed in the community||38.7||||4.0|
|Dispensed in hospitals||55.1||68.6||121.3|
|Dispensed in the community|||||||
The usage of temozolomide in primary care is negligible and carmustine is not used at all in primary care. Therefore, since the primary care usage is so low, sub-national data cannot be provided for patient confidentiality reasons.
Data for temzolomide at cancer network level were published by the Department as part of the review undertaken by the National Cancer director on the variations in usage of cancer drugs appraised by the National Institute for Health and Clinical Excellence. The report is available on the Department's website at:
|Next Section||Index||Home Page|